Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Hemophilia gene therapy Hemgenix sets record for world’s most expensive drug 

By Brian Buntz | November 23, 2022

CSL, including CSL Behring in the Drug Discovery & Development Pharma 50FDA has approved CSL Behring’s (ASX: CSL) Hemgenix (etranacogene dezaparvovec), an adenovirus-associated virus–based gene therapy for adults with hemophilia B.

The price tag for the gene therapy — the first for hemophilia B — is $3.5 million. The drug is administered as a single infusion.

Hemophilia B is a genetic bleeding disorder caused by missing or defective blood coagulation factor IX, a clotting protein. The condition affects men more often than women.

People with moderate to severe hemophilia B typically receive regular prophylactic infusions of factor IX replacement therapy, frequently several times per week.

In the Phase 3 HOPE-B study, Hemgenix demonstrated “a profound and impressive decrease in bleeding rates compared to standard of care,” said Dr. Steve Pascoe, CSL Behring’s senior vice president of clinical and therapeutic strategy, in an R&D investor briefing.

“We also saw that factor IX levels rose dramatically above and beyond what you would expect with prophylactic replacement therapy,” Pascoe added.

“The price tag of $3.5M for the new hemophilia B gene therapy Hemgenix is pressuring insurers and drug companies to work together to create value-based agreements for high-cost life-saving treatments,” said Girisha Fernando, CEO and Founder of Lyfegen. “I applaud this effort and encourage more agreements that benefit patients, insurers, and drug companies. Advanced technologies today can help with implementing complex agreements like these, ensuring payment for agreed-upon rebates.”

In the HOPE-B trial, Hemgenix lowered the rate of annual bleeds. A total of 94% of patients discontinued factor IX prophylaxis and were prophylaxis-free.

The FDA approval came earlier than expected. It covers patients on Factor IX prophylaxis therapy or with a history of life-threatening hemorrhage or serious spontaneous bleeding episodes.

Hemophilia B affects roughly one in 25,000 male births, according to the National Organization for Rare Disorders (NORD). It is less prevalent than hemophilia A, which occurs in about one in 5,000 male births.

CSL Behring is optimistic about the durability of the treatment. The company had observed that factor IX levels were maintained up to 24 months after initiation of the therapy. In addition, following a Hemgenix infusion, study participants had mean factor IX activity of 39% at six months and 36.7% at 24 months.

The 24-month data gives the company “enhanced confidence in the durability of etranacogene,” Pascoe said.

Before CSL Behring announced the price of the gene therapy, Pascoe said that etranacogene represented “a true step up in value proposition in the treatment benefits conferred to patients.” To support that assertion, he pointed to the increased protection from bleeding.

“What is less obvious is the impact of the disease and medicalization has on patients,” Pascoe said. “Currently, even well-treated hemophilia B patients are recommended to avoid strenuous sports and, indeed, to avoid occupations that involve some degree of risk.”

In the HOPE-B clinical trial, 51 out of 54 patients (94%) who received Hemgenix discontinued prophylaxis therapy.

“We believe that, with the Factor IX levels we’re seeing, a large number of patients will actually be able to normalize their lives,” Pascoe added. “That, we believe, is a substantive benefit that has not been seen with any other treatments.”


Filed Under: Cell & gene therapy, clinical trials, Hematology
Tagged With: CSL Behring, Hemgenix
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

How Thermo Fisher’s KingFisher PlasmidPro crunches hours of plasmid prep to 5 minutes hands-on
Can space help heal hearts? ISS study charts new path for stem cell therapy
MIT team designs gene circuits for tighter control in gene therapy study
Meet STITCHR, the retrotransposon-based gene editor that enables large, scarless DNA insertions
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE